Shinozaki Takeshi, Matsuura Kazuto, Okano Wataru, Tomioka Toshifumi, Nishiya Yukio, Machida Michiko, Hayashi Ryuichi
Department of Head and Neck Surgery, National Cancer Center Hospital East, Kashiwa 277-8577, Japan.
Medical Science & Operations Division, Rakuten Medical K.K., Tokyo 158-0094, Japan.
Cancers (Basel). 2023 Jul 26;15(15):3795. doi: 10.3390/cancers15153795.
Photoimmunotherapy is a novel cancer treatment that recently became covered by national health insurance in Japan, but treatment decision-making remains challenging for unresectable advanced or recurrent head and neck cancer. We aimed to clarify the characteristics of patients for whom photoimmunotherapy was indicated by a retrospective chart review. Patients aged ≥20 years diagnosed with advanced or recurrent head and neck cancer who started receiving systemic therapy at the National Cancer Center Hospital East from January 2016 through December 2020 were retrospectively analyzed. Before and after first-line systemic therapy, patients were classified into 3 groups according to eligibility for photoimmunotherapy: eligible, potentially eligible, and ineligible. In total, of 246 patients evaluated-194 after exclusions were analyzed-108 were deemed ineligible for treatment. Of the remaining 86 patients, 8 were considered potentially eligible and 9 eligible. Of the nine eligible patients, four became ineligible after receiving first-line systemic therapy due to disease progression. Our results suggest that the indication of photoimmunotherapy should be considered before, during, and after systemic therapy for unresectable locally advanced or recurrent head and neck cancer.
光免疫疗法是一种新型癌症治疗方法，最近在日本已被纳入国家健康保险范围，但对于不可切除的晚期或复发性头颈癌，治疗决策仍然具有挑战性。我们旨在通过回顾性病历审查来阐明适合光免疫疗法的患者特征。对2016年1月至2020年12月在国立癌症中心东医院开始接受全身治疗的年龄≥20岁、被诊断为晚期或复发性头颈癌的患者进行回顾性分析。在一线全身治疗前后，根据光免疫疗法的适用性将患者分为3组：适合、可能适合和不适合。总共评估了246例患者，排除后分析了194例，其中108例被认为不适合治疗。在其余86例患者中，8例被认为可能适合，9例适合。在这9例适合的患者中，4例在接受一线全身治疗后因疾病进展而变得不适合。我们的结果表明，对于不可切除的局部晚期或复发性头颈癌，在全身治疗之前、期间和之后都应考虑光免疫疗法的适应症。
